Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
Rhea-AI Summary
Apotex announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both eligible for 180-day shared exclusivity. These generics are AB rated to Merck’s JANUVIA and JANUMET and are indicated as adjuncts to diet and exercise for adults with type 2 diabetes.
The sitagliptin product comes in 25 mg, 50 mg, and 100 mg strengths, while the combination product is offered in 50 mg/500 mg and 50 mg/1,000 mg strengths. Both medicines are distributed through U.S. wholesalers and distributors.
AI-generated analysis. Not financial advice.
Positive
- U.S. launch of sitagliptin tablets with 180-day shared exclusivity eligibility
- U.S. launch of sitagliptin and metformin tablets with 180-day shared exclusivity eligibility
- AB-rated generics to JANUVIA and JANUMET expand Apotex diabetes portfolio
- Multiple strengths and bottle sizes increase flexibility for type 2 diabetes treatment
Negative
- Generic launches introduce new competition for Merck’s JANUVIA and JANUMET in the U.S. market
News Market Reaction – MRK
On the day this news was published, MRK declined 0.82%, reflecting a mild negative market reaction. This price movement removed approximately $2.44B from the company's valuation, bringing the market cap to $294.75B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MRK is up 0.42% while key diabetes/large-cap peers show mixed moves: NVO -1.3%, AZN -0.96%, NVS -0.37%, ABBV +2.09%, JNJ +0.14%. With no peers in the momentum scanner and only JNJ having unrelated trial news, the reaction appears stock-specific rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Oncology trial update | Positive | -3.0% | 5-year Phase 2b data for intismeran autogene plus KEYTRUDA in melanoma. |
| May 29 | Regulatory designation | Positive | -1.0% | FDA Breakthrough Therapy designation for calderasib plus KEYTRUDA in NSCLC. |
| May 28 | Conference participation | Neutral | -0.3% | Announcement of participation in Jefferies Global Healthcare Conference. |
| May 26 | Dividend declaration | Positive | -2.2% | Declared Q3 2026 dividend of $0.85 per share with July 8 payment date. |
| May 22 | EU opinion oncology | Positive | +5.6% | Positive EU CHMP opinion for KEYTRUDA plus Padcev in bladder cancer. |
Recent MRK news has often seen share price weakness even on positive clinical or regulatory updates, with the notable exception of a strong positive reaction to the EU CHMP opinion.
Over the past few weeks, MRK has reported several oncology and regulatory milestones, including positive 5-year Phase 2b data with intismeran autogene plus KEYTRUDA on Jun 1, 2026 and an FDA Breakthrough Therapy designation for calderasib on May 29, 2026, both followed by modest share declines. A Jefferies conference appearance on Jun 4, 2026 and a $0.85 quarterly dividend declared for payment on Jul 8, 2026 also saw soft price reactions. In contrast, a positive EU CHMP opinion for KEYTRUDA plus Padcev on May 22, 2026 coincided with a strong gain, highlighting selective investor enthusiasm for de‑risking regulatory decisions.
Market Pulse Summary
This announcement highlights Apotex’s U.S. launch of sitagliptin and sitagliptin–metformin tablets, AB rated to Merck’s JANUVIA and JANUMET and eligible for 180-day shared exclusivity, expanding generic options in type 2 diabetes. For MRK, this context intersects with an already active period of oncology and regulatory news, including a positive EU CHMP opinion and Breakthrough Therapy designation. Investors may watch how diabetes franchise trends evolve alongside MRK’s broader pipeline, while also tracking future updates on KEYTRUDA-based combinations and other growth drivers.
Key Terms
sitagliptin medical
metformin hydrochloride medical
type 2 diabetes mellitus medical
therapeutic equivalence regulatory
fixed-dose combination medical
AI-generated analysis. Not financial advice.
Type 2 diabetes affects millions of adults in
Sitagliptin tablets are AB rated (per FDA's Approved Drug Products with Therapeutic Equivalence Evaluations) to JANUVIA® (Merck) and are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.1
The product is available in 25 mg, 50 mg, and 100 mg strengths, packaged in 30‑count and 90‑count bottles.
Sitagliptin and metformin hydrochloride tablets are AB rated to JANUMET® (Merck) and are indicated as a prescription medicine that contains a fixed-dose combination of sitagliptin and metformin hydrochloride, sitagliptin and metformin, and can be used as an adjunct to diet and exercise to lower blood sugar in adults with type 2 diabetes.2 The product is available in 50 mg/500 mg and 50 mg-1,000 mg count bottles.
"Expanding access to high-quality, affordable medicines remain central to our mission," said Christine Baeder, President, Apotex USA and LATAM. "By introducing these products, we are seeking to strengthen the continuity of care for adults managing chronic conditions and supporting the healthcare professionals who rely on consistent, reliable treatment options for their patients."
Both products are being made available through
__________________________ |
1 Product Guide: https://www.apotex.com/products/us/detail.asp?m=68610 |
About Apotex
Apotex Corp., headquartered in Weston, Florida, is a subsidiary of Apotex Health Corp. We improve everyday access to innovative medicines and health products for millions of people around the world, offering a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally—including in the United States, Mexico, and India—Apotex Health Corp is the largest Canadian based pharmaceutical company and a health partner of choice across the Americas for pharmaceutical licensing and product acquisitions.
Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities laws. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances. Forward-looking information in this news release includes statements regarding the exclusivity period of the launched products and our goal of expanding access to high quality, affordable medicines. This forward-looking information is based on a number of opinions, estimates and assumptions that, while considered by Apotex to be appropriate and reasonable as of the date of this release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, those related to the Apotex's ability to expand its portfolio with the product launches described herein, Apotex's ability to expand access to high‑quality, affordable medicines, Apotex's ability to achieve its mission, Apotex's ability to strengthen the continuity of care for adults managing chronic conditions and supporting healthcare professionals who rely on treatment options for their patients, Apotex's ability to improve everyday access to products, Apotex becoming the partner of choice across the Americas for licensing and product acquisitions and other risks. Apotex undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws.
JANUVIA® and JANUMET® are registered trademarks of Merck Sharp & Dohme LLC.
View original content to download multimedia:https://www.prnewswire.com/news-releases/apotex-launches-sitagliptin-tablets-and-sitagliptin-and-metformin-hydrochloride-tablets-eligible-for-180-day-shared-exclusivity-302789161.html
SOURCE Apotex Corp.